Journal
RHEUMATOLOGY
Volume 55, Issue 5, Pages 775-779Publisher
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/kev346
Keywords
lupus; biologics; review
Categories
Funding
- UCB celltech
- Roche/Chugai
- Pfizer
- Abbvie
- Merck
- Mennarini
- Eli-lilly
Ask authors/readers for more resources
With the explosion in biologics use in rheumatology, newer and smarter ways of using these drugs in different diseases have been advocated. SLE has to date been at the back of the biologics algorithms. Recently, the US Food and Drug Administration and European Medicines Evaluation Agency licensed belimumab for use in SLE, the first drug in > 30 years. A clinical review of the evidence that underlies the use of belimumab and other biologics in SLE reveals possible reasons why the results are not as spectacular as they are in other diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available